Transfusion and Apheresis Science
Volume 36, Issue 2 , Pages 169-172 , April 2007

Therapeutic apheresis for myositises

Received 18 December 2006 ,Accepted 4 January 2007.

References 

  1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–982
  2. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscular Disord. 2004;14(5):337–345
  3. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–347
  4. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–407
  5. Selva-O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martinez-Gomez X, Vilardell-Tarres M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum. 2006;55(5):791–798
  6. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005;84(4):231–249
  7. Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006;65(12):1635–1638
  8. Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford). 2002;41(1):7–13
  9. Patten E. Therapeutic plasmapheresis and plasma exchange. Crit Rev Clin Lab Sci. 1986;23(2):147–175
  10. Khatri BO, Luprecht G, Weiss SA. Plasmapheresis and immunosuppressive drug therapy in polymyositis. Muscle Nerve. 1982;5(7):568–569
  11. Brewer EJ, Giannini EH, Rossen RD, Patten B, Barkley E. Plasma exchange therapy of a childhood onset dermatomyositis patient. Arthritis Rheum. 1980;23(4):509–513
  12. Dau PC. Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients. Arch Neurol. 1981;38(9):544–552
  13. Bennington JL, Dau PC. Patients with polymyositis and dermatomyositis who undergo plasmapheresis therapy. Pathologic findings. Arch Neurol. 1981;38(9):553–560
  14. Clarke CR, Dyall-Smith DJ, Mackay IR, Emery P, Jennens ID, Becker G. Plasma exchange in dermatomyositis/polymyositis: beneficial effects in three cases. J Clin Lab Immunol. 1988;27(3):149–152
  15. Herson S, Lok C, Roujeau JC, Coutellier A, Etienne SD, Revuz J, et al. Plasma exchange in dermatomyositis and polymyositis. Retrospective study of 38 cases of plasma exchange. Ann Med Interne (Paris). 1989;140(6):453–455
  16. Lok C, Herson S, Roujeau JC, Revuz J, Gerard A, Godeau P. Plasma exchange in dermatomyositis. A retrospective study of 21 cases. Ann Dermatol Venereol. 1989;116(3):219–224
  17. Cherin P, Auperin I, Bussel A, Pourrat J, Herson S. Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases. Clin Exp Rheumatol. 1995;13(2):270–271
  18. Cherin P, Herson S. Immunoglobulins or plasma exchange? New treatment methods in polymyositis and dermatomyositis: plasma exchange and intravenous immunoglobulins. Ann Med Interne (Paris). 1993;144(8):521–525
  19. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992;326(21):1380–1384
  20. Smith JW, Weinstein R For the AHCKL. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion. 2003;43(6):820–822
  21. Euler H, Shroeder J. Antibody depletion and cytotoxic drug therapy in severe systemic lupus erythematosus. Transfus. Sci. 1992;13:167–184
  22. Bussel A, Boulechfar H, Naim R. Immunoglobulins or plasma exchange? Synchronization of plasma exchange and intravenous polyvalent immunoglobulins. A consecutive study of 11 patients. Ann Med Interne (Paris). 1993;144(8):532–538
  23. Nydegger UE, Sturzenegger T. Treatment of autoimmune disease: synergy between plasma exchange and intravenous immunoglobulins. Ther Apher. 2001;5(3):186–192
  24. Arlet JB, Dimitri D, Pagnoux C, Boyer O, Maisonobe T, Authier FJ, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord. 2006;16(5):334–336
  25. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol. 2006;33(5):1021–1026
  26. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005;32(7):1369–1370
  27. Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol. 2005;11(5):264–266

PII: S1473-0502(07)00031-6

doi: 10.1016/j.transci.2007.01.008

Transfusion and Apheresis Science
Volume 36, Issue 2 , Pages 169-172 , April 2007

Article Tools